Last Updated : June 2, 2023
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Adcetris | Brentuximab vedotin | Systemic Anaplastic Large Cell Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Adcetris | Brentuximab vedotin | Hodgkin Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Adcetris | brentuximab vedotin | Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine | Active | |||
| Adcetris (Resubmission) | Brentuximab Vedotin | Hodgkin lymphoma (HL) | Do not reimburse | Complete | ||
| Adcirca | Tadalafil | Pulmonary arterial hypertension | List with clinical criteria and/or conditions | Complete | ||
| Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder | Do not list | Complete | ||
| Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder | Withdrawn | |||
| Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder, Adult | Do not list | Complete | ||
| Adempas | Riociguat | Pulmonary arterial hypertension (WHO group 1) | List with clinical criteria and/or conditions | Complete | ||
| Adempas | Riociguat | Chronic thromboembolic pulmonary hypertension | List with criteria/condition | Complete |
Last Updated : June 2, 2023